Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. (Q51366559)

4 April 2018

title

Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. (English)

1 reference

4 April 2018

0 references

1 reference

1 reference

Abhishek Pallava

1

1 reference

4 April 2018

Rakesh K Chadda

series ordinal

2

1 reference

4 April 2018

Mamta Sood

series ordinal

3

1 reference

4 April 2018

R Lakshmy

series ordinal

4

1 reference

4 April 2018

publication date

24 October 2011

1 reference

4 April 2018

Nordic Journal of Psychiatry

published in

1 reference

4 April 2018

volume

66

1 reference

4 April 2018

issue

3

1 reference

4 April 2018

page(s)

215-221

1 reference

4 April 2018

Excess mortality of schizophrenia. A meta-analysis

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

BMI does not accurately predict overweight in Asian Indians in northern India

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Prevalence of metabolic syndrome in an Indian urban population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Metabolic syndrome prevalence, dietary intake, and cardiovascular risk profile among overweight and obese adults 18-50 years old from the United Arab Emirates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.621977

10.3109/08039488.2011.621977

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

22017264

1 reference

4 April 2018